NASDAQ:ALZN Alzamend Neuro (ALZN) Stock Price, News & Analysis $3.81 -0.08 (-2.06%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$3.62▼$4.1650-Day Range$3.52▼$6.3952-Week Range$3.27▼$73.41Volume26,595 shsAverage Volume8,253 shsMarket Capitalization$30.41 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Alzamend Neuro alerts: Email Address Ad DTIHow a $0.25 cent option contract makes my top traders feelIf you don’t know me, I’ve been in the markets for over 40 years… but recently, I’ve discovered a breakthrough that might be my favorite strategy of ALL time! While I kept the finer details of these $0.25 Cent Trades under wraps until recently…Click now to see for yourself what $0.25 Cent Trades is all about About Alzamend Neuro Stock (NASDAQ:ALZN)Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.Read More ALZN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALZN Stock News HeadlinesJuly 26 at 5:40 AM | americanbankingnews.comAlzamend Neuro, Inc. (NASDAQ:ALZN) Short Interest Up 153.3% in JulyJuly 19, 2024 | seekingalpha.comALZN Alzamend Neuro, Inc.July 26, 2024 | Crypto 101 Media (Ad)Brace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range. But that could change soon. Very soon.May 9, 2024 | finance.yahoo.comAlzamend Neuro Announces Agreement for Registered Direct Offering and Concurrent Private Placement for an Aggregate of up to $25 MillionMay 9, 2024 | finance.yahoo.comEXCLUSIVE: Alzamend Neuro To Raise Up To $25M Via Private Placement Of Preferred SharesMay 7, 2024 | msn.comAlzamend Neuro Halts Equity Offering Program, Prioritizing Shareholder Value Amid Strategic Shift, Shares SlideMay 7, 2024 | finance.yahoo.comAlzamend Neuro Announces Termination of At-the-Market Equity Offering ProgramApril 24, 2024 | msn.comAlzamend Neuro And 2 Other Stocks Under $5 Insiders Are BuyingJuly 26, 2024 | Crypto 101 Media (Ad)Brace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range. But that could change soon. Very soon.April 17, 2024 | msn.comAlzamend Neuro (ALZN) Price Target Decreased by 16.00% to 21.42March 26, 2024 | msn.comALZN Stock Earnings: Alzamend Neuro Misses EPS for Q3 2024February 24, 2024 | msn.comAlzamend Neuro (ALZN) Price Target Increased by 25.00% to 25.50February 13, 2024 | realmoney.thestreet.comMaxim gets more bearish on Alzamend Neuro, downgrades sharesFebruary 3, 2024 | msn.comAlzamend Neuro Risks Nasdaq Delisting Over Price DeficiencyDecember 19, 2023 | markets.businessinsider.comBuy Rating for Alzamend Neuro Amid Promising Alzheimer’s Drug Trials and Market PotentialDecember 18, 2023 | msn.comALZN Stock Earnings: Alzamend Neuro Beats EPS for Q1 2024December 18, 2023 | msn.comALZN Stock Earnings: Alzamend Neuro Reported Results for Q2 2024December 11, 2023 | finance.yahoo.comAlzamend Neuro Receives FDA "Study May Proceed" Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder PatientsSee More Headlines Receive ALZN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alzamend Neuro and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings9/13/2023Today7/26/2024Fiscal Year End4/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ALZN CUSIPN/A CIK1677077 Webwww.alzamend.com Phone844-722-6303FaxN/AEmployees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.9895) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,880,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-612.26% Return on Assets-255.65% Debt Debt-to-Equity RatioN/A Current Ratio0.16 Quick Ratio0.16 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.71 per share Price / Book0.80Miscellaneous Outstanding Shares800,000Free Float7,140,000Market Cap$3.03 million OptionableNo Data Beta0.03 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Stephan Jackman (Age 47)CEO & Director Comp: $434.24kMr. David J. Katzoff (Age 61)Chief Financial Officer Comp: $116.67kMr. Milton Charles Ault III (Age 54)Founder & Vice Chairman Mr. Henry C. W. Nisser Esq. (Age 55)Executive VP, General Counsel & Director Comp: $50kMr. Kenneth S. Cragun CPA (Age 63)Senior Vice President of Finance Key CompetitorsImunonNASDAQ:IMNNVaccinexNASDAQ:VCNXTraws PharmaNASDAQ:TRAWMonopar TherapeuticsNASDAQ:MNPREterna TherapeuticsNASDAQ:ERNAView All CompetitorsInsiders & InstitutionsVirtu Financial LLCBought 26,482 shares on 5/20/2024Ownership: 0.385%Milton C Ault IIIBought 100 shares on 4/19/2024Total: $690.00 ($6.90/share)Milton C Ault IIIBought 33 shares on 4/1/2024Total: $300.30 ($9.10/share)Milton C Ault IIIBought 500 shares on 1/5/2024Total: $5,100.00 ($10.20/share)Milton C Ault IIIBought 50 shares on 12/26/2023Total: $450.00 ($9.00/share)View All Insider TransactionsView All Institutional Transactions ALZN Stock Analysis - Frequently Asked Questions How have ALZN shares performed this year? Alzamend Neuro's stock was trading at $8.90 at the beginning of the year. Since then, ALZN stock has decreased by 57.2% and is now trading at $3.81. View the best growth stocks for 2024 here. How were Alzamend Neuro's earnings last quarter? Alzamend Neuro, Inc. (NASDAQ:ALZN) released its quarterly earnings data on Wednesday, September, 13th. The company reported ($6.00) earnings per share (EPS) for the quarter. When did Alzamend Neuro's stock split? Shares of Alzamend Neuro reverse split on Tuesday, July 16th 2024. The 1-10 reverse split was announced on Tuesday, July 16th 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, July 16th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Alzamend Neuro IPO? Alzamend Neuro (ALZN) raised $12 million in an initial public offering (IPO) on Tuesday, June 15th 2021. The company issued 2,500,000 shares at a price of $5.00 per share. Spartan Capital Securities, LLC acted as the underwriter for the IPO and -- was co-manager. Who are Alzamend Neuro's major shareholders? Top institutional investors of Alzamend Neuro include Concourse Financial Group Securities Inc.. Insiders that own company stock include Milton C Ault III, Milton C Ault III, Milton C Ault III, David J Katzoff, Mark Gustafson, Stephan Jackman and Lynne Fahey Mcgrath. View institutional ownership trends. How do I buy shares of Alzamend Neuro? Shares of ALZN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ALZN) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredWhy is NVDA stumbling?July is historically the best month of the year for U.S. stocks. So why are everyone’s favorite tech stocks...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alzamend Neuro, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alzamend Neuro With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.